Ehave, Inc. (EHVVF)

[sweet crude]

NEWS!!!

https://finance.yahoo.com/news/rushnet-inc-announces-agreement-ehave-123000884.html

Rushnet, Inc Announces Agreement with Ehave for Mental Health Lab Testing

ALPHARETTA, GA / ACCESSWIRE / May 9, 2023 / RushNet, Inc (OTC PINK:RSHN), (the "Company") announces agreement with Ehave, Inc. (OTC Pink: EHVVF), announces agreement with Ehave, Inc. (OTC Pink: EHVVF), for laboratory testing in the psychedelic and mental health sectors.

The company announced that it has signed a Memorandum of Understanding (MOU) with Ehave, Inc., which is a digital therapeutics provider for the psychedelic sector and the mental health sector, for the development of laboratory testing solutions and healthcare data management for the mental and wellness sectors.

HeliosDX's Behavioral Toxicology Test provides enhanced visibility of patients' health, allowing for a quicker diagnosis and treatment. This panel aims to help patients improve their quality of life by managing chronic conditions in a steady manner.

Both companies have agreed to explore genetic testing for DNA biomarkers, as well as pre-screening mental surveys that will provide insight into the individual's potential risk of adverse reactions when using ketamine and other psychedelics to treat mental illness.

Genetics may play a major role in determining an individual's response to psychedelic assisted psychotherapy. The gene variant CYP2B6 affects the metabolism of ketamine in 10-20% of people who carry a specific CYP2B6. The HTR2A mutation, carried by approximately 20% of the population, can also affect how people respond to serotonin. Serotonin is the primary mechanism for action of serotonergic psychoactives like psilocybin.

In the future, both parties will explore gene markers for other cognitive disorders like Alzheimer's.